We are extremely pleased that data from our Phase III psoriasis trials of ISA247 will be presented to audiences that represent both dermatology and transplantation. We continue to be encouraged by the data generated in the SPIRIT extension trial and we believe ISA247 will continue to demonstrate continued efficacy with minimal toxicity.

We have more than 150 patents pending and 16 patents issued related to our ISA247 technology. These patents include compound claims, methods of manufacture, use claims and analytical methods. Our intellectual property position continues to be strengthened with the addition of this new patent. We will continue to pursue additional patentable claims for ISA247 where appropriate.